Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET –SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics ...

Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017)Global Statistical ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial ...

The update comes as the therapy’s regulatory application awaits a decision from the U.S. Food and Drug Administration later ...

Deramiocel, the lead product candidate, is still in late-stage development and has not yet received regulatory approvals, which raises concerns about the company's ability to bring products to market.

High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:CAPR), and it's important for retail traders to take note. \This activity came to our attention today through ...

Capricor Therapeutics Inc CAPR shares are trading lower Friday afternoon after the biotech company reported a ...

Capricor Therapeutics (CAPR) upgraded to Buy as FDA accepts HOPE-3 for Deramiocel in DMD cardiomyopathy; PDUFA Aug 22, 2026.

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics. The biotech company’s stock jumped 18% ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript March 12, 2026 Operator: Good afternoon, ladies ...